<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04767295</url>
  </required_header>
  <id_info>
    <org_study_id>HNCH-ESCC-001</org_study_id>
    <nct_id>NCT04767295</nct_id>
  </id_info>
  <brief_title>A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC)</brief_title>
  <official_title>PD-1 Monoclonal Antibody Camrelizumab Combined With Albumin Paclitaxel and Platinum for Neoadjuvant Treatment of Adcanced Esophageal Squamous Cell Carcinoma (ESCC): A Single-center, Single-arm Phase II Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hunan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hunan Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of camrelizumab combined with albumin paclitaxel and&#xD;
      platinum chemotherapy in the preoperative treatment of locally advanced thoracic esophageal&#xD;
      squamous cell carcinoma&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary outcome:&#xD;
&#xD;
      1. Analysis of prognosis efficacy of patients: pathologic complete response (pCR)&#xD;
&#xD;
      Secondary outcome:&#xD;
&#xD;
      Overall survival(OS), Progressive-free survival(PFS), Disease control rate(DCR), Objective&#xD;
      response rate(ORR), and the proportion of subjects who completed all treatments and radical&#xD;
      resection (R0);&#xD;
&#xD;
      Explorative outcome:&#xD;
&#xD;
      To explore the efficacy of ultrasound gastroscopy, PET/CT, peripheral circulating blood tumor&#xD;
      cell (CTC) detection and CTC-based immunofluorescence detection of PD-L1 antibody for the&#xD;
      treatment of locally advanced ESCC with camrelizumab combined with albumin paclitaxel and&#xD;
      platinum and potential biomarkers for predicting the efficacy of camrelizumab, including but&#xD;
      not limited to immunohistochemical detection of PD-L1 expression in tumor specimens, T cell&#xD;
      receptor (TCR) sequencing analysis in peripheral blood, and esophageal microbiome Analysis,&#xD;
      etc.; patients' quality of life&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patients fulfilling Eligibility Criteria will be included in our study. ESCC participants in this study will be given intravenous administration of SHR-1210 (200mg/3w) combined with albumin paclitaxel (260 mg/m2) plus carboplatin chemotherapy. Every three weeks for a cycle of treatment, which will be conducted twice, and minimally invasive surgery within 5-8 weeks after the last administration. Treatments will be administrated until disease progression, unacceptable adverse events (AE), concomitant diseases that hinder continued treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective remission rate (ORR)</measure>
    <time_frame>through study completion, an average of 2 year</time_frame>
    <description>evaluated by researchers based on the RECIST 1.1 standard</description>
  </primary_outcome>
  <primary_outcome>
    <measure>progression free survival (PFS)</measure>
    <time_frame>through study completion, an average of 2 year</time_frame>
    <description>evaluated by researchers based on the RECIST 1.1 standard</description>
  </primary_outcome>
  <primary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>through study completion, an average of 2 year</time_frame>
    <description>evaluated by researchers based on the RECIST 1.1 standard</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease control rate(DCR)</measure>
    <time_frame>through study completion, an average of 2 year</time_frame>
    <description>evaluated by researchers based on the RECIST 1.1 standard</description>
  </primary_outcome>
  <primary_outcome>
    <measure>pathologic complete response (pCR)</measure>
    <time_frame>through study completion, an average of 2 year</time_frame>
    <description>evaluated by researchers based on the RECIST 1.1 standard</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Camrelizumab, Albumin Paclitaxel, Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ESCC participants in this study will be given intravenous administration of Camrelizumab (200mg/3w) combined with albumin paclitaxel (260 mg/m2) plus carboplatin chemotherapy. Every three weeks for a cycle of treatment, which will be conducted twice, and minimally invasive surgery within 5-8 weeks after the last administration.&#xD;
Treatments will be administrated until disease progression, unacceptable adverse events (AE), concomitant diseases that hinder continued treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab, Albumin Paclitaxel, Carboplatin</intervention_name>
    <description>Intravenous administration of Camrelizumab (200mg/3weeks); Intravenous administration of albumin paclitaxel (260 mg/m2/3weeks); Intravenous administration of carboplatin (AUC 4/3weeks)</description>
    <arm_group_label>Camrelizumab, Albumin Paclitaxel, Carboplatin</arm_group_label>
    <other_name>SHR1210</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Sign the informed consent form before any trial-related procedures are implemented;&#xD;
&#xD;
          -  Age 18-70 years, both men and women;&#xD;
&#xD;
          -  pathologically confirmed thoracic esophageal squamous cell carcinoma;&#xD;
&#xD;
          -  The clinical staging is T3-4a (potentially resectable) N0-2 (PET/CT or cervical, chest&#xD;
             and abdomen CT + intra-esophageal ultrasound staging, except those with N3 stage);&#xD;
             T1-2N1-2 can be included in the study, T4b, T1-2N0, carcinoma in situ are all&#xD;
             excluded;&#xD;
&#xD;
          -  The longitudinal length of the tumor is less than 8cm;&#xD;
&#xD;
          -  Patients can be followed up for a long time and cooperate with treatment;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1; life&#xD;
             expectancy&gt; 6 months;&#xD;
&#xD;
          -  No other treatments including chemotherapy, radiotherapy, Chinese medicine treatment,&#xD;
             etc. were used before selection.&#xD;
&#xD;
          -  There is no history of radiotherapy in the chest cavity.&#xD;
&#xD;
          -  Hematopoietic function is good before treatment, which is defined as absolute&#xD;
             neutrophil count ≥1.5×109/L, platelet count ≥100×109/L, hemoglobin ≥90g/L (No blood&#xD;
             transfusion within 7 days or no erythropoietin (EPO) dependence);&#xD;
&#xD;
          -  Liver function is good before treatment, defined as total bilirubin level ≤ upper&#xD;
             normal limit (ULN); aspartate aminotransferase (AST) and alanine aminotransferase&#xD;
             (ALT) levels ≤ 1.5 times ULN;&#xD;
&#xD;
          -  Good renal function before treatment, defined as serum creatinine ≤ 1.5 times ULN or&#xD;
             calculated creatinine clearance ≥ 60 ml/min (Cockcroft-Gault formula); urine protein&#xD;
             in routine examination of urine is less than 2+, or 24-hour urine Protein quantitative&#xD;
             &lt;1g;&#xD;
&#xD;
          -  Good coagulation function before treatment, defined as International Normalized Ratio&#xD;
             (INR) or Prothrombin Time (PT) ≤ 1.5 times ULN; if the subject is receiving&#xD;
             anticoagulation therapy, they can also be included in this trail as long as the PT is&#xD;
             within the intended range of anticoagulation drugs;&#xD;
&#xD;
          -  For female subjects of childbearing age, they should have a negative urine or serum&#xD;
             pregnancy test within 3 days before receiving the first study drug administration&#xD;
             (cycle 1, day 1). If the urine pregnancy test result cannot be confirmed as negative,&#xD;
             blood pregnancy test is required. If there is a risk of conception, male and female&#xD;
             patients need to use high-efficiency contraception (ie, a method with a failure rate&#xD;
             of less than 1% per year) and continue until at least 180 days after stopping the&#xD;
             trial treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical history of malignant tumors in other parts, excluding curable non-melanoma&#xD;
             skin cancer, radically excised cervical carcinoma in situ, and malignant tumors that&#xD;
             have been cured for more than 5 years;&#xD;
&#xD;
          -  Pregnant or breast-feeding patients who have fertility but have not taken&#xD;
             contraceptive measures;&#xD;
&#xD;
          -  Those who are allergic to the study drug camrelizumab, paclitaxel or platinum;&#xD;
&#xD;
          -  Previous peripheral neuropathy (whether primary or secondary);&#xD;
&#xD;
          -  Severe comorbidities: large-area myocardial infarction, myocardial infarction within 6&#xD;
             months, history of cerebral infarction, heart function ≥ grade III, history of mental&#xD;
             illness and severe diabetes, severe pulmonary dysfunction, or other conditions that&#xD;
             are not suitable for surgery;&#xD;
&#xD;
          -  Participate in other clinical trials at present or within four weeks before being&#xD;
             selected;&#xD;
&#xD;
          -  Simultaneous treatment with other anti-cancer drugs (including anti-cancer Chinese&#xD;
             medicine);&#xD;
&#xD;
          -  Have a history of organ transplantation;&#xD;
&#xD;
          -  Those who cannot cooperate because of dementia or mental disorders;&#xD;
&#xD;
          -  Cachexia, weight loss over the past six months&gt; 10%;&#xD;
&#xD;
          -  Histology contains non-squamous carcinoma components, such as small cell carcinoma,&#xD;
             adenocarcinoma, etc.;&#xD;
&#xD;
          -  Have received the following therapies in the past: anti-PD-1, anti-PD-L1 or anti-PD-L2&#xD;
             drugs or for another stimulating or synergistic inhibition of T cell receptors (for&#xD;
             example, CTLA-4, OX-40, CD137) drug;&#xD;
&#xD;
          -  Have received systemic treatment with anti-cancer indications Chinese patent medicines&#xD;
             or immunomodulatory drugs (including thymosin, interferon, interleukin) within 2 weeks&#xD;
             before the first administration, or received major surgical treatment within 3 weeks&#xD;
             before the first administration; those with previous partial gastrectomy, bowel&#xD;
             surgery history, or those who are not suitable for minimally invasive surgery are&#xD;
             excluded from the group;&#xD;
&#xD;
          -  There is clinically active diverticulitis, abdominal abscess, gastrointestinal&#xD;
             obstruction; received solid organ or blood system transplantation;&#xD;
&#xD;
          -  Active autoimmune diseases that require systemic treatment (such as the use of&#xD;
             disease-relieving drugs, corticosteroids, or immunosuppressants) occurred within 2&#xD;
             years before the first administration. Alternative therapies (such as thyroxine,&#xD;
             insulin, or physiological corticosteroids for adrenal or pituitary insufficiency,&#xD;
             etc.) are not considered systemic treatments;&#xD;
&#xD;
          -  Diagnosis of immunodeficiency or receiving systemic glucocorticoid therapy or any&#xD;
             other form of immunosuppressive therapy within 14 days before the first administration&#xD;
             of the study; physiological dose of glucocorticoids (≤10 mg/ day of prednisone or its&#xD;
             equivalent) is allowed;&#xD;
&#xD;
          -  Before starting treatment, have not fully recovered from the toxicity and/or&#xD;
             complications caused by any intervention (ie ≤ Grade 1 or reach baseline, excluding&#xD;
             fatigue or hair loss);&#xD;
&#xD;
          -  A history of non-infectious pneumonia requiring glucocorticoid therapy within 1 year&#xD;
             before the first administration or current existing in interstitial lung disease;&#xD;
&#xD;
          -  Active infections such as tuberculosis that require systemic treatment;&#xD;
&#xD;
          -  Known mental illness or drug abuse that may affect compliance with the test&#xD;
             requirements;&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) infection (ie HIV 1/2 antibody&#xD;
             positive);&#xD;
&#xD;
          -  Untreated active hepatitis B; Note: Hepatitis B subjects who meet the following&#xD;
             criteria are also eligible for selection: HBV viral load must be &lt;1000 copies/ml (200&#xD;
             IU/ml) before the first dose, and the test Patients should receive anti-HBV therapy&#xD;
             during the entire study chemotherapy drug treatment period to avoid viral&#xD;
             reactivation. For subjects with anti-HBc (+), HBsAg (-), anti-HBs (-) and HBV viral&#xD;
             load (-), prophylactic anti-HBV treatment is not required, but virus reactivation&#xD;
             needs to be closely monitored; active Subjects infected with HCV (HCV&#xD;
             antibody-positive and HCV-RNA level is higher than the lower limit of detection) ;&#xD;
&#xD;
          -  Live vaccine has been vaccinated within 30 days before the first dose (cycle 1, day&#xD;
             1); Note: It is allowed to receive inactivated virus vaccine for seasonal influenza&#xD;
             within 30 days before the first administration; however, it is not allowed to receive&#xD;
             live attenuated influenza vaccine for intranasal administration;&#xD;
&#xD;
          -  The medical history or disease evidence that may interfere with the test results,&#xD;
             prevent the subjects from participating in the study, abnormal treatment or laboratory&#xD;
             test values, or other conditions that the investigator believes are not suitable for&#xD;
             inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>wangwenxiang@hnca.org.cn wangwenxiang@hnca.org.cn</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hunan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wenxiang Wang</last_name>
    <phone>+8613808454225</phone>
    <email>wangwenxiang@hnca.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wenxiang Wang</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenxiang Wang</last_name>
      <phone>+8613808454225</phone>
      <email>wangwenxiang@hnca.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>January 18, 2021</study_first_submitted>
  <study_first_submitted_qc>February 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2021</study_first_posted>
  <last_update_submitted>February 19, 2021</last_update_submitted>
  <last_update_submitted_qc>February 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PD-1 Checkpoint Inhibitor</keyword>
  <keyword>Neoadjuvant Therapy</keyword>
  <keyword>Esophageal Squamous Cell Carcinoma (ESCC)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>Data can be shared no earlier than 1 year following the date of publication</ipd_time_frame>
    <ipd_access_criteria>please contact the principal investigator of this study or correspondence author of published work</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

